Skip to main content

Table 5 Response rate according to the clinical factors and the genotypes

From: Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker

  

Overall frequency

Responder

 
  

No. of Pts

%

No. of Pts

RR (%)

p-value*

Age

≤ 55

31

42.5

15

48.4

0.501

 

> 55

42

57.5

17

40.5

 

Performance

ECOG 0–1

60

82.2

28

46.7

0.295

 

ECOG 2

13

17.8

4

30.8

 

Histotype

Intestinal

47

67.1

19

40.4

0.557

 

Diffuse

23

32.9

11

47.8

 
 

unknown

3

    

Disease status

Initial stage IV

54

74.0

27

50.0

0.107

 

Relapsed

19

26.0

5

26.3

 

TS in 5'UTR#

2R/2R, 2R/3C, 3C/3C

21

28.8

7

33.3

0.285

 

2R/3G, 3C/3G, 3G/3G

51

69.9

24

47.1

 
 

unknown

1

1.4

   

TS 6-bp deletion in 3'UTR

-6/-6

40

54.8

22

55.0

0.034

 

+6/+6 or +6/-6

33

45.2

10

30.3

 

GSTP1-Ile105Val (A105G)

A/A

44

60.3

22

50.0

0.191

 

A/G or G/G

29

39.7

10

34.5

 

ERCC-Asn118Asn

C/C

40

54.8

17

42.5

0.800

 

C/T or T/T

33

45.2

15

57.5

 

ERCC-C8092A

C/C

44

60.3

18

40.9

0.535

 

C/A or A/A

29

39.7

14

48.3

 

XPD- Arg156Arg

C/C

23

31.5

6

26.1

0.038

 

C/A or A/A

50

54.0

26

52.0

 

XPD-Asp312Asn

G/G

8

11.0

1

12.5

0.072

 

G/A

65

89.0

31

47.7

 

XPD-Lys751Gln

A/A

62

84.9

28

45.2

0.746

 

A/C or C/C

11

15.1

4

36.4

 

XRCC1-Arg399Gln

G/G

48

65.8

21

43.8

0.984

 

G/A or A/A

25

34.2

11

44.0

 
  1. RR, response rate.
  2. *p-value for the comparison between response rate and genotypes, based on Pearson's χ 2 test (using Fisher's exact test, if N ≤ 5).
  3. #Analysis of the TS-5'UTR VNTR polymorphism with G/C SNP change in 3R allele carriers.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us